109 related articles for article (PubMed ID: 8522638)
1. Effect of aging on atenolol pharmacokinetics and pharmacodynamics.
Sowinski KM; Forrest A; Wilton JH; Taylor AM; Wilson MF; Kazierad DJ
J Clin Pharmacol; 1995 Aug; 35(8):807-14. PubMed ID: 8522638
[TBL] [Abstract][Full Text] [Related]
2. Effects of tedisamil, atenolol and their combination on heart and rate-dependent QT interval in healthy volunteers.
Démolis JL; Martel C; Funck-Brentano C; Sachse A; Weimann HJ; Jaillon P
Br J Clin Pharmacol; 1997 Oct; 44(4):403-9. PubMed ID: 9354317
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and pharmacodynamic interaction of single doses of valsartan and atenolol.
Czendlik CH; Sioufi A; Preiswerk G; Howald H
Eur J Clin Pharmacol; 1997; 52(6):451-9. PubMed ID: 9342580
[TBL] [Abstract][Full Text] [Related]
4. Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers.
Luzier AB; Killian A; Wilton JH; Wilson MF; Forrest A; Kazierad DJ
Clin Pharmacol Ther; 1999 Dec; 66(6):594-601. PubMed ID: 10613615
[TBL] [Abstract][Full Text] [Related]
5. Renal handling of drugs in the healthy elderly. Creatinine clearance underestimates renal function and pharmacokinetics remain virtually unchanged.
Fliser D; Bischoff I; Hanses A; Block S; Joest M; Ritz E; Mutschler E
Eur J Clin Pharmacol; 1999 May; 55(3):205-11. PubMed ID: 10379636
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of atenolol in clinically normal cats.
Quiñones M; Dyer DC; Ware WA; Mehvar R
Am J Vet Res; 1996 Jul; 57(7):1050-3. PubMed ID: 8807020
[TBL] [Abstract][Full Text] [Related]
7. Effect of itraconazole on the pharmacokinetics of atenolol.
Lilja JJ; Backman JT; Neuvonen PJ
Basic Clin Pharmacol Toxicol; 2005 Dec; 97(6):395-8. PubMed ID: 16364056
[TBL] [Abstract][Full Text] [Related]
8. Effects of orange juice on the pharmacokinetics of atenolol.
Lilja JJ; Raaska K; Neuvonen PJ
Eur J Clin Pharmacol; 2005 Jul; 61(5-6):337-40. PubMed ID: 15983823
[TBL] [Abstract][Full Text] [Related]
9. Absorption pharmacokinetics of atenolol in patients with the Marfan syndrome.
Phelps SJ; Alpert BS; Ward JL; Pieper JA; Lima JJ
J Clin Pharmacol; 1995 Mar; 35(3):268-74. PubMed ID: 7608315
[TBL] [Abstract][Full Text] [Related]
10. Comparative pharmacokinetics and pharmacodynamics of propranolol and atenolol in normolipaemic and hyperlipidaemic obese subjects.
Wójcicki J; Jaroszynska M; Droździk M; Pawlik A; Gawrońska-Szklarz B; Sterna R
Biopharm Drug Dispos; 2003 Jul; 24(5):211-8. PubMed ID: 12784321
[TBL] [Abstract][Full Text] [Related]
11. [Effect of hyperlipidemia on pharmacodynamics of propranolol and atenolol].
Telatyńska-Smieszek B; Wójcicki J; Droździk M; Gawrońska-Szklarz B; Sulzyc-Bielicka V; Sterna R
Pol Arch Med Wewn; 2004 Jan; 111(1):45-51. PubMed ID: 15088420
[TBL] [Abstract][Full Text] [Related]
12. Effect of rifampicin on the pharmacokinetics of atenolol.
Lilja JJ; Juntti-Patinen L; Neuvonen PJ
Basic Clin Pharmacol Toxicol; 2006 Jun; 98(6):555-8. PubMed ID: 16700816
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of atenolol enantiomers in 12 Chinese healthy men.
Wang XM; Yu XY; Lin SG
Zhongguo Yao Li Xue Bao; 1999 Apr; 20(4):367-70. PubMed ID: 10452127
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic and pharmacodynamic evaluation of atenolol during and after pregnancy.
Hurst AK; Shotan A; Hoffman K; Johnson J; Goodwin TM; Koda R; Elkayam U
Pharmacotherapy; 1998; 18(4):840-6. PubMed ID: 9692658
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics of controlled-release metoprolol: a comparison with atenolol.
Blomqvist I; Westergren G; Sandberg A; Jonsson UE; Lundborg P
Eur J Clin Pharmacol; 1988; 33 Suppl():S19-24. PubMed ID: 3371390
[TBL] [Abstract][Full Text] [Related]
16. Beta-blocker duration of action and implications for therapy.
Kostis JB
Am J Cardiol; 1990 Nov; 66(16):60G-62G. PubMed ID: 1978546
[TBL] [Abstract][Full Text] [Related]
17. The effect on heart rate of combining single-dose fingolimod with steady-state atenolol or diltiazem in healthy subjects.
Kovarik JM; Lu M; Riviere GJ; Barbet I; Maton S; Goldwater DR; Schmouder RL
Eur J Clin Pharmacol; 2008 May; 64(5):457-63. PubMed ID: 18196225
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic-pharmacodynamic modelling of S(-)-atenolol in rats: reduction of isoprenaline-induced tachycardia as a continuous pharmacodynamic endpoint.
van Steeg TJ; Freijer J; Danhof M; de Lange EC
Br J Pharmacol; 2007 Jun; 151(3):356-66. PubMed ID: 17420778
[TBL] [Abstract][Full Text] [Related]
19. Effects of selective and nonselective beta-adrenergic blockade on mechanisms of exercise conditioning.
Wolfel EE; Hiatt WR; Brammell HL; Carry MR; Ringel SP; Travis V; Horwitz LD
Circulation; 1986 Oct; 74(4):664-74. PubMed ID: 2875812
[TBL] [Abstract][Full Text] [Related]
20. Steady-state fluctuation and variability of betaxolol and atenolol plasma levels.
Kunka RL; Wong YY; Andersen RL; Haack DG
Ther Drug Monit; 1989 Sep; 11(5):523-7. PubMed ID: 2573178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
